Global Recurrent Glioblastoma Pipeline Insight Report | 50+ Companies & 50+ Drugs

December 08 11:05 2022
Global Recurrent Glioblastoma Pipeline Insight Report | 50+ Companies & 50+ Drugs

DelveInsight’s, “Recurrent Glioblastoma Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.


Key takeaways from the Recurrent Glioblastoma Pipeline Report

  • DelveInsight’s Recurrent Glioblastoma Pipeline analysis depicts a robust space with 50+ active players working to develop 50+ Recurrent Glioblastoma pipeline treatment therapies.
  • Some of the key Recurrent Glioblastoma companies proactively working to develop potential drug candidates to improve the Recurrent Glioblastoma treatment options include Ascletis, VBL Therapeutics, Genexine, PharmAbcine, Oncoceutics, Istari Oncology, CNS Pharmaceuticals, Oblato, Nerviano Medical Sciences, VAXIMM AG, OX2 Therapeutics, Erasca, Midatech, MediciNova, Karyopharm Therapeutics, Jiangsu Hengrui Medicine, , QED Therapeutics, Apogenix, Eli Lilly and Company, Incyte Corporation, Accendatech, Crimson BioPharm, CANbridge Life Sciences, OncoSynergy, VBI Vaccines, Calidi Biotherapeutics, Plus Therapeutics and many more.
  • Essential Recurrent Glioblastoma pipeline therapies include ASC40, VB-111, GX-I7, Olinvacimab, ONC 201, Lerapolturev, Berubicin Hydrochloride, OKN-007, NMS-03305293, VXM01, hP1A8, ERAS-801, MTX110, MN-166, Selinexor, Camrelizumab, BGJ398, Asunercept, Abemaciclib, INCMGA00012, ACT001, CM 93, CAN008, Bemcentinib, CD200AR L, Retifanlimab, OS2966, VBI-1901, NNV2, 186RNL and many others.
  • In the coming years, the Recurrent Glioblastoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The Recurrent Glioblastoma Companies and academics that are working to assess challenges and seek opportunities that could influence Recurrent Glioblastoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.


Recent Developmental Activities in the Recurrent Glioblastoma Pipeline

  • In August 2022, Calidi Biotherapeutics announced that City of Hope received US Food and Drug Administration (FDA) authorization to proceed with a Phase I physician-sponsored clinical trial that will use Calidi’s licensed oncolytic virotherapy platform, NSC-CRAd-S-pk7 (NeuroNova), a cutting-edge therapeutic candidate comprising tumor-tropic neural stem cells delivering an oncolytic adenovirus selectively to tumor sites in patients with recurrent high-grade glioma (Calidi’s NNV-2 program).
  • In August 2022, Plus Therapeutics, presented positive data from two ongoing clinical trials of its lead investigational drug, Rhenium-186 Nanoliposome (186RNL), in the treatment of recurrent glioblastoma (GBM) and leptomeningeal metastases (LM).
  • In July 2021, Berubicin was granted fast track designation by the FDA for the treatment of glioblastoma multiforme (GBM) following recurrence, according to the company responsible for the agent, CNS Pharmaceuticals.
  • In March 2021, OncoSynergy, announced that the first patient was treated in the Company’s First-in-Human Phase I clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma. OS2966 is a first-in-class immunotherapy, and the first ever anti-CD29 (beta 1 integrin) therapeutic to reach human trials.
  • In August 2020, ERC Belgium announced promising interim results in the Phase II clinical trial for ERC1671. The trial, ERC1671/GM CSF/Cyclophosphamide+Bevacizumab vs Placebo, is a double-blind, placebo-controlled study of 84 patients with recurrent GBM. Interim unblinding and analysis of the first 10 patients from the study demonstrated the following results in patients treated with ERC1671. Approximately 10% of the patients receiving ERC1671 experienced total recovery and survived longer than 3 years when treated following GBM recurrence and after receiving standard of care treatment. In contrast, no spontaneous remissions were observed in the control group and all patients experienced tumor progression.


Request a sample and discover more about the Recurrent Glioblastoma pipeline report offerings @ Recurrent Glioblastoma Pipeline Outlook Report


Recurrent Glioblastoma Overview

Recurrent glioblastoma is a possibility that oncologists – and patients – must keep in mind during and after an initial course of treatment. Because it can be difficult to completely remove a tumor during surgery, there is always a possibility that the cancer might come back after a period of remission. As a result, survivors are typically scheduled for follow-up appointments and surveillance imaging every few months after the completion of their initial treatments. Glioblastoma can come back anywhere in the brain or spinal cord. However, most recurrences are found near the site of the original tumor. Without treatment, the median survival with glioblastoma is only a few months, but even with treatment, survival is frequently only around one year.


Recurrent Glioblastoma Pipeline Report

In the Recurrent Glioblastoma pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Recurrent Glioblastoma collaborations, licensing, mergers and acquisition, funding, designations and other product related detail.


Recurrent Glioblastoma Emerging Drugs Profile

ASC40: Ascletis

ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN), a key enzyme which regulates de novo lipogenesis (DNL). ASC40 inhibits energy supply and disturbs membrane phospholipid composition of tumor cells by blocking de novo lipogenesis. In January 2022, Ascletis Pharma Inc. announced the dosing of the first patient in the Phase III registration clinical trial of ASC40 combined with bevacizumab for treatment of recurrent glioblastoma (rGBM). The Phase II study, completed in the U.S., in patients with rGBM has shown that the objective response rate (ORR) for ASC40 plus Bevacizumab treatment was 65% including a complete response (CR) of 20% and a partial response (PR) of 45%. 

GX-I7: Genexine

GX-I7 is a long-acting human IL-7 which is essential for homeostatic T cell proliferation and improves lymphopenia, typically induced by chemotherapy or radiation therapy. The safety has been proved via phase I clinical trial in healthy volunteers and phase Ib and Ib/2 Clinical trials are being conducted to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics and efficacy. 

Olinvacimab: PharmAbcine

Olinvacimab is an anti-angiogenic antibody that neutralizes the VEGF/VEGFR2 pathway, thus inhibiting tumor growth and metastasis. It blocks the binding of all VEGFR ligands such as VEGF-A, VEGF-C and VEGF-D to VEGFR2. To gain nutrients and oxygen needed for growth, tumor cells release these VEGF ligands which promote angiogenesis (a formation of new blood vessels) that will enhance tumor blood supply. Binding of olinvacimab to VEGFR2 will result in the inhibition of VEGF-mediated tumor angiogenesis.


Recurrent Glioblastoma Pipeline Assessment

There are approx. 50+ key companies which are developing the therapies for Recurrent Glioblastoma. The companies which have their Recurrent Glioblastoma drug candidates in the most advanced stage, i.e. phase III include, Ascletis.


Find out more about the disease and recent cancer research developments @ Recurrent Glioblastoma Ongoing Clinical Trials Analysis


 Recurrent Glioblastoma Pipeline Therapeutics Analysis

The Recurrent Glioblastoma Pipeline report proffers an integral view of the Recurrent Glioblastoma emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action and Route of Administration.


Scope of the Recurrent Glioblastoma Pipeline Report

  • Coverage: Global
  • Therapeutic Assessment By Recurrent Glioblastoma Product Type: Mono, Combination, Mono/Combination
  • Therapeutic Assessment By Recurrent Glioblastoma Clinical Trial Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III, Pre-registration, Inactive candidates
  • Therapeutics Assessment By Recurrent Glioblastoma Route of Administration: Inhalation, Intravenous, Oral, Intranasal, Subcutaneous, Parenteral
  • Therapeutics Assessment By Recurrent Glioblastoma Molecule Type: Antibody, Antisense oligonucleotides, Immunotherapy, Monoclonal antibody, Peptides, Protein, Recombinant protein, Small molecule, Stem Cell, Vaccine
  • Therapeutics Assessment By Recurrent Glioblastoma Mechanism of Action: Fatty acid synthetase complex inhibitors, Interleukin 7 replacements; T lymphocyte stimulants, Angiogenesis inhibitors, Antibody-dependent cell cytotoxicity, Vascular endothelial growth factor A inhibitors, Gene transference, Vascular disrupting agents, Poly(ADP-ribose) polymerase inhibitors, Immunomodulators, Oxygen radical scavengers, Sulfatase inhibitors, Cell death stimulants, Epidermal growth factor receptor antagonists, Immunomodulators, Immunostimulants, Angiogenesis inhibitors; Antibody-dependent cell cytotoxicity
  • Key Recurrent Glioblastoma Companies: Ascletis, Genexine, PharmAbcine, VAXIMM AG, WPD Pharmaceuticals, Accendatech USA Inc., Midatech Ltd, MediciNova, Kadmon Corporation, LLC, Istari Oncology, Inc, Bristol-Myers Squibb, Novartis, Jiangsu Hengrui Medicine, Peloton Therapeutics, Inc., Karyopharm Therapeutics, VBL Therapeutics, Nerviano Medical Sciences, Acerta Pharma BV, Basilea Pharmaceutica, DNAtrix, Inc., NanoPharmaceuticals LLC, Erasca, Inc., Oblato, Inc., OX2 Therapeutics, Crimson Biopharm Inc., Merck Sharp & Dohme LLC, Transgene, CANbridge Life Sciences Ltd., Eli Lilly and Company, Arcus Biosciences, Inc., Incyte Corporation, BerGenBio ASA, Istari Oncology, Inc., Chimerix
  • Key Recurrent Glioblastoma Pipeline Therapies:  ASC40, VB-111, GX-I7, Olinvacimab, ONC 201, Lerapolturev, Berubicin Hydrochloride, OKN-007, NMS-03305293, VXM01, hP1A8, ERAS-801, MTX110, MN-166, Selinexor, Camrelizumab, BGJ398, Asunercept, Abemaciclib, INCMGA00012, ACT001, CM 93, CAN008, Bemcentinib, CD200AR L, Retifanlimab, OS2966, VBI-1901, and others.


Table of Content

  1. Introduction
  2. Executive Summary
  3. Recurrent Glioblastoma: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Recurrent Glioblastoma – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. ASC40: Ascletis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. GX-I7: Genexine
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. VXM01: VAXIMM AG
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Recurrent Glioblastoma Key Companies
  21. Recurrent Glioblastoma Key Products
  22. Recurrent Glioblastoma- Unmet Needs
  23. Recurrent Glioblastoma- Market Drivers and Barriers
  24. Recurrent Glioblastoma- Future Perspectives and Conclusion
  25. Recurrent Glioblastoma Analyst Views
  26. Recurrent Glioblastoma Key Companies
  27. Appendix


Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Recurrent Glioblastoma drugs?
  • How many Recurrent Glioblastoma drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Recurrent Glioblastoma?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Recurrent Glioblastoma therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Recurrent Glioblastoma and their status?
  • What are the key designations that have been granted to the emerging drugs?


For further information on the Recurrent Glioblastoma Pipeline therapeutics, reach out to Recurrent Glioblastoma Treatment Landscape

Media Contact
Company Name: DelveInsight LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09193216187
Address:304 S. Jones Blvd #2432,
City: Las Vegas
State: United States
Country: India